Literature DB >> 30316683

ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.

Christopher J Bakkenist1, James J Lee2, John C Schmitz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30316683      PMCID： PMC6561466          DOI： 10.1016/j.clcc.2018.09.001

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  17 in total

1.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

Authors:  Philip M Reaper; Matthew R Griffiths; Joanna M Long; Jean-Damien Charrier; Somhairle Maccormick; Peter A Charlton; Julian M C Golec; John R Pollard
Journal:  Nat Chem Biol       Date:  2011-04-13       Impact factor: 15.040

2.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

Authors:  Greg Yothers; Michael J O'Connell; Carmen J Allegra; J Philip Kuebler; Linda H Colangelo; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-08-22       Impact factor: 44.544

3.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Authors:  Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

4.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

Review 5.  Brd4 shields chromatin from ATM kinase signaling storms.

Authors:  Serah Choi; Christopher J Bakkenist
Journal:  Sci Signal       Date:  2013-09-17       Impact factor: 8.192

6.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation.

Authors:  Christopher J Bakkenist; Michael B Kastan
Journal:  Nature       Date:  2003-01-30       Impact factor: 49.962

7.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Radiation therapy induces the DNA damage response in peripheral blood.

Authors:  Christopher J Bakkenist; R Kenneth Czambel; David A Clump; Joel S Greenberger; Jan H Beumer; John C Schmitz
Journal:  Oncotarget       Date:  2013-08

9.  A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.

Authors:  Luis I Toledo; Matilde Murga; Rafal Zur; Rebeca Soria; Antonio Rodriguez; Sonia Martinez; Julen Oyarzabal; Joaquin Pastor; James R Bischoff; Oscar Fernandez-Capetillo
Journal:  Nat Struct Mol Biol       Date:  2011-05-08       Impact factor: 15.369

10.  Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.

Authors:  Andrew D Beggs; Enric Domingo; Megan McGregor; Mikael Presz; Elaine Johnstone; Rachel Midgley; David Kerr; Dahmane Oukrif; Marco Novelli; Muti Abulafi; Shirley V Hodgson; Wakkas Fadhil; Mohammad Ilyas; Ian P M Tomlinson
Journal:  Oncotarget       Date:  2012-11
View more
  7 in total

1.  Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.

Authors:  Agnieszka Bojko; Joanna Czarnecka-Herok; Agata Charzynska; Michal Dabrowski; Ewa Sikora
Journal:  Cells       Date:  2019-11-23       Impact factor: 6.600

2.  Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.

Authors:  Georgios I Papageorgiou; Evangelos Fergadis; Nikos Skouteris; Evridiki Christakos; Sergios A Tsakatikas; Evangelos Lianos; Christos Kosmas
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

3.  Antitumor Activity of lncRNA NBAT-1 via Inhibition of miR-4504 to Target to WWC3 in Oxaliplatin-Resistant Colorectal Carcinoma.

Authors:  Chen Li; Xu Li
Journal:  J Healthc Eng       Date:  2022-04-21       Impact factor: 3.822

4.  Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report.

Authors:  Yu Cheng; Gang Wu; Simeng Zhang; Yunpeng Liu; Jinglei Qu; Xiujuan Qu
Journal:  Onco Targets Ther       Date:  2021-07-15       Impact factor: 4.147

5.  Oxaliplatin-Induced DHX9 Phosphorylation Promotes Oncogenic Circular RNA CCDC66 Expression and Development of Chemoresistance.

Authors:  Ya-Chi Lin; Ya-Shan Yu; Hui-Hsuan Lin; Kuei-Yang Hsiao
Journal:  Cancers (Basel)       Date:  2020-03-16       Impact factor: 6.639

6.  The SOX9-MMS22L Axis Promotes Oxaliplatin Resistance in Colorectal Cancer.

Authors:  Yiqiang Liu; Hong Wu; Tao Luo; Qiyu Luo; Ziyu Meng; Ying Shi; Feifei Li; Mingxin Liu; Xinhao Peng; Junjie Liu; Chuan Xu; Weizhong Tang
Journal:  Front Mol Biosci       Date:  2021-05-27

Review 7.  Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.

Authors:  Fabio Catalano; Roberto Borea; Silvia Puglisi; Andrea Boutros; Annalice Gandini; Malvina Cremante; Valentino Martelli; Stefania Sciallero; Alberto Puccini
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.